AEZS Aeterna Zentaris Inc.

0  -2%
Previous Close 3.00
Open 3.00
Price To book 6.24
Market Cap 39.83M
Shares 13,500,000
Volume 120,491
Short Ratio 2.93
Av. Daily Volume 219,256

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 data released January 4, 2017 - trial failed. Announced March 30, 2017 intention to file NDA 3Q 2017.
Macimorelin Acetate - Macrilen
Adult Growth Deficiency
Noted January 30, 2017 completion of Phase 3 trial with data due April 2017.
Endometrial cancer

Latest News

  1. Aeterna Zentaris Mails Management Information Circular in Connection with Annual Meeting of Shareholders
  2. Aeterna Zentaris shares surge almost 14% premarket on news of NDA for growth hormone drug
  3. Aeterna Zentaris Intends to File NDA with Respect to Macrilen™ in Third Quarter of 2017
  4. Aeterna Zentaris Announces At the Market Issuance Program
  5. Æterna Zentaris, Inc. :AEZS-US: Earnings Analysis: Q4, 2016 By the Numbers : March 27, 2017
  6. Aeterna Zentaris reports 4Q loss
  7. Aeterna Zentaris Reports Fourth Quarter and Full-Year 2016 Financial and Operating Results
  8. Aeterna Zentaris Announces EMA Pediatric Committee Agreement on the Pediatric Investigation Plan for Macrilen™
  9. Aeterna Zentaris to Announce Fourth Quarter and Full-Year 2016 Financial and Operating Results on March 15, 2017
  10. Aeterna Zentaris Announces Presentation Regarding Macrilen™ at 99th Annual Meeting of the Endocrine Society
  11. Tenet Healthcare (THC) to Divest Operations to Amedisys
  12. Aeterna Zentaris Announces Zoptrex™ Presentation in Prostate Cancer at 2017 Genitourinary Cancers Symposium
  13. Aeterna Zentaris Announces Plans to Pursue FDA Registration of Macrilen™
  14. Aeterna Zentaris to Present at the 2nd Annual Disruptive Growth & Healthcare Conference
  15. Aeterna Zentaris to Present at the 2017 BIO CEO and Investor Conference
  16. Drug Approvals Expected to Rise as Trump Pledges to Speed Up Approval Process: Latest Reports on AEterna Zentaris and Momenta Pharmaceuticals
  17. Expectations Run High At AEterna Zentaris Inc. (USA) (AEZS) As Two New Drugs Enter Final Testing Phases
  18. Aeterna Zentaris Announces Completion of Zoptrex™ Pivotal Phase 3 Clinical Trial in Advanced Endometrial Cancer; Expects to Report Top-Line Results in April 2017
  19. Biotech Industry Outperforming Markets in 2017: Latest Reports on Pulmatrix and Aeterna Zentaris
  20. Dryships, Agile Therapeutics in Thursday’s 52-Week Low Club